During the conference, Dr. Jimmy Chang highlighted TaiMed’s lead asset, TMB-365/380, a long-acting dual-antibody HIV maintenance therapy dosed once every two months (Q2M), which has received U.S. FDA clearance to enter a Phase 2b clinical trial, targeting the global HIV maintenance therapy market. Key highlights include:
Leading Clinical Profile:
Based on existing clinical data, TMB-365/380 demonstrated superb viral suppression at Week 24, with no cases of virologic failure observed. Compared to currently marketed or late-stage competing regimens, TMB-365/380 offers several differentiated advantages, including no requirement for resistance or sensitivity testing, no observed resistance concerns, minimal injection-site pain, and a favorable safety profile, positioning it as a potential First-in-Class / Best-in-Class long-acting antibody-based HIV therapy.
Clear Value Inflection Points:
The Phase 2b clinical trial of TMB-365/380 is expected to complete last patient in (LPI) by mid-2026, with interim Phase 2b data anticipated between late 2026 and early 2027. This milestone will represent a critical inflection point for significantly enhancing the valuation and momentum of strategic licensing and co-development partnerships. Based on market assumptions, if TMB-365/380 achieves approximately 30% penetration of the long-acting HIV market, peak annual sales potential is estimated at USD 3–4 billion.
Beyond strengthening its leadership in HIV, TaiMed is actively expanding into the significantly larger autoimmune disease market. Dr. Jimmy Chang emphasized that the global autoimmune therapeutics market is projected to reach USD 400 billion by 2033, more than seven times the size of the HIV market.
Key strategic focus areas include:
TMB-365 ADC Platform:
TaiMed’s proprietary CD4⁺-targeted antibody-drug conjugate (ADC) platform is designed to selectively bind CD4⁺ cells—central not only to HIV pathogenesis but also to multiple autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, psoriasis, and systemic lupus erythematosus.
Precision Medicine Advantage:
The ADC technology enables direct intracellular delivery and payload release, achieving therapeutic efficacy with less than 1% of systemic drug exposure, thereby substantially reducing the systemic toxicity and adverse effects commonly associated with conventional therapies such as TNF inhibitors and JAK inhibitors. With the rapid growth of the global autoimmune therapeutics market, TaiMed believes its CD4-targeted ADC platform has the potential to emerge as a next-generation precision immunotherapy solution.
On the commercial front, Trogarzo®, the world’s first monoclonal antibody approved for multi-drug-resistant (MDR) HIV, is currently marketed in the United States and is expanding into additional regions including MENA, Hong Kong, Macau, Taiwan, and Vietnam.
In parallel, TaiMed leverages its in-house cGMP manufacturing facility in Zhubei, Taiwan, not only to support internal clinical and commercial programs but also to provide CDMO (Contract Development and Manufacturing Organization) services, enhancing operational flexibility and generating stable cash flows. This dual-engine model integrates innovation-driven R&D with scalable manufacturing capabilities.
During the presentation, Dr. Jimmy Chang referenced Gilead Sciences’ historical growth trajectory, noting that TaiMed is approaching a similar strategic inflection point defined by platform validation and portfolio diversification. With Trogarzo® validating the CD4 platform, and the continued advancement of TMB-365/380 and the ADC pipeline, TaiMed aims to significantly expand its enterprise value from its current base, with a long-term goal of becoming a global biopharmaceutical company with a USD 10 billion enterprise value by around 2030.
Dr. Jimmy Chang concluded by emphasizing that TaiMed’s development roadmap is clearly defined and execution-driven. The Company will continue to strengthen collaborations with global investors and strategic partners through high-quality clinical data generation, disciplined strategic partnerships, and global market expansion, with the objective of delivering sustainable long-term value to both shareholders and patients worldwide.
Contact CDMO Service